兄弟科技(002562.SZ):拉考沙胺注射液獲批上市
格隆匯3月3日丨兄弟科技(002562.SZ)公佈,公司全資子公司浙江兄弟藥業有限公司(簡稱“兄弟藥業”)於近日收到國家藥品監督管理局核准簽發的拉考沙胺注射液的《藥品註冊證書》(證書編號:2025S00546)。
拉考沙胺注射液適用於4歲及以上癲癇患者部分性發作的聯合治療。拉考沙胺是控制鈉通道慢失活的第三代抗癲癇藥物,通過調節鈉離子通道活性減少神經元興奮性,具有耐受性好、安全性高的特點。
根據米內網數據顯示,拉考沙胺注射液2024年上半年國內市場規模約1.15億元,同比增長約214%。該產品已被納入國家醫保乙類目錄,並已納入第十批國家藥品集中採購目錄。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.